Polish Drugmaker Adamed Announces Expansion Plans

Polish drug producer Adamed has announced that it will spend PLN20mn (US$6.54mn) on R&D and expanding its laboratory facilities. The company claims to have spent PLN 53mn (S$17.33mn) on research since 2000.

Meanwhile, Adamed is working on a possible treatment for lung and bladder cancers, known provisionally as Aserin. Clinical trials in Poland have begun, although the company does not expect a US approval before 2009. The company, which is targeting regional export markets in Slovakia and Hungary, is a leading local generics producer. Its Zolafren antipsychotic has recently been the subject of a dispute with US drug major Eli Lilly.